Terbinafine for Ringworm Treatment
Terbinafine is highly effective for tinea corporis and tinea cruris when used topically for 1 week or orally for 1-4 weeks, but for tinea capitis, its efficacy depends critically on the causative organism—it is first-line only for Trichophyton species (not Microsporum species). 1
Tinea Corporis and Tinea Cruris (Body and Groin Ringworm)
Topical Terbinafine (Preferred for Localized Disease)
- Apply terbinafine 1% cream once daily for 7 days for tinea corporis/cruris 2, 3
- This short regimen achieves 84% mycological cure rates and is significantly superior to placebo 2
- The solution formulation applied twice daily for 1 week is equally effective (65% cure rate) 3
Oral Terbinafine (For Extensive Disease or Treatment Failure)
- Standard dose: 250 mg once daily for 1-4 weeks 4, 5
- One-week therapy with oral terbinafine 250 mg daily achieves complete mycological clearance in tinea cruris/corporis 4
- Important caveat: Recent data shows poor cure rates (20-33%) after 4 weeks of treatment, with no additional benefit from doubling the dose to 500 mg daily 6
- This suggests emerging resistance patterns that clinicians must consider 6, 7
Tinea Capitis (Scalp Ringworm)
Critical Species-Specific Considerations
Terbinafine efficacy is highly organism-dependent and should guide treatment selection 1:
- For Trichophyton species (T. tonsurans, T. violaceum, T. soudanense): Terbinafine is first-line therapy 1
- For Microsporum species (M. canis, M. audouinii): Griseofulvin is superior; terbinafine has poor efficacy 1
Why Terbinafine Fails Against Microsporum
The pharmacokinetic explanation is crucial: terbinafine is not excreted in sweat or sebum of prepubertal children and cannot be incorporated into the hair shaft, preventing it from reaching the scalp surface where Microsporum arthroconidia are located 1
Dosing for Tinea Capitis (When Appropriate)
Weight-based dosing for 2-4 weeks 1:
- < 20 kg: 62.5 mg daily
- 20-40 kg: 125 mg daily
- > 40 kg: 250 mg daily
Treatment Principles
- Oral therapy is mandatory—topical therapy alone is not recommended for tinea capitis 1
- Treatment choice should be directed by causative organism or local epidemiology 1
- The shorter treatment course (2-4 weeks vs 6-8 weeks for griseofulvin) may improve compliance 1
- Endpoint is mycological cure, not clinical cure—repeat mycology sampling until clearance is achieved 1
FDA-Approved Indications
Critical limitation: Oral terbinafine is FDA-approved only for onychomycosis (nail infections), not for tinea corporis, cruris, or capitis 8. Use for other tinea infections represents off-label prescribing, though it is widely practiced and supported by guidelines.
Safety Considerations
Monitoring Requirements
- Obtain baseline liver function tests before initiating oral therapy 8
- Hepatotoxicity can occur in patients with or without pre-existing liver disease 8
- Patients should report persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or pale stools immediately 8
Common Adverse Effects
- Gastrointestinal disturbances and rashes occur in < 8% of patients 1
- Only 0.8% require treatment discontinuation 1
Serious but Rare Adverse Effects
- Taste disturbance (including complete loss) can be severe, prolonged (>1 year), or permanent 8
- Smell disturbance may also be prolonged or permanent 8
- Depressive symptoms have been reported 8
Treatment Failure Management
When terbinafine fails, consider 1:
- Non-compliance or suboptimal drug absorption
- Organism resistance (increasingly reported with Indian genotype VIII of T. mentagrophytes) 7
- Wrong organism (Microsporum species in tinea capitis)
- Reinfection from untreated contacts
For tinea capitis treatment failure with ongoing positive mycology but clinical improvement, continue therapy for an additional 2-4 weeks 1. If no clinical improvement, switch to second-line therapy (itraconazole for mixed infections, or griseofulvin for Microsporum) 1
Emerging Resistance Concerns
Terbinafine-resistant dermatophytes are an emerging threat, particularly the Indian genotype VIII of T. mentagrophytes with SQLE gene mutations 7. These strains may require alternative antifungals like topical miconazole or ciclopirox 7. This resistance pattern explains recent poor cure rates even with doubled doses 6.